Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2022 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial...
January 03, 2022 07:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
December 17, 2021 08:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Added to NASDAQ Biotechnology Index

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
November 10, 2021 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting – – Investigational New...
August 11, 2021 16:02 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 – – Received Orphan Drug Designation for CFT7455 for the...
August 11, 2021 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
June 21, 2021 16:01 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
June 21, 2021 08:00 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins – – CFT7455 Resulted...
June 16, 2021 19:51 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Pricing of Public Offering

WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
June 14, 2021 16:12 ET | Source: C4 Therapeutics, Inc.

C4 Therapeutics Launches Proposed Public Offering

WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...